| Japanese |
|---|
| Title | 新しい肝機能イメージング剤99mTc-GSAの第2相臨床試験 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 鳥塚莞爾*, 河相吉**, 工藤正俊***, 北川真一****, 久保田佳嗣****, 田中敬正**, 日野恵*****, 池窪勝治***** |
|---|
| Authors(kana) | |
|---|
| Organization | *福井医科大学, **関西医科大学放射線科, ***神戸市立中央市民病院内科, ****関西医科大学第三内科, *****神戸市立中央市民病院核医学科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 29 |
|---|
| Number | 1 |
|---|
| Page | 85-95 |
|---|
| Year/Month | 1992/1 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」肝臓に特異的に存在するアシアロ糖蛋白受容体をターゲットとした新しい肝機能イメージング剤99mTc-GSAを81例の肝疾患患者に投与し, 安全性および肝機能評価における有効性につき検討した. 99mTc-GSAに起因すると考えられる自・他覚症状の変化, 臨床検査値異常および抗GSA抗体の産生は認められなかった. 99mTc-GSA静注直後から60分間ダイナミックデータ収集を行い, 経時的に肝シンチグラムを得るとともに, 心臓および肝臓の関心領域内のカウントから99mTc-GSAの血中消失および肝集積の指標を求めた. 慢性肝炎, 肝硬変などの慢性肝疾患患者54例において, 99mTc-GSAの血中消失および肝集積は肝機能障害の進行に伴って有意に遅延した. また, 大きな肝癌を有する患者, 閉塞性黄疸の患者および急性肝炎の患者においても99mTc-GSAの所見は肝機能を反映した. 以上の結果から, 99mTc-GSAは肝機能診断薬として臨床使用が可能であると考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Technetium-99m-DTPA-galactosyl human serum albumin (99mTc-GSA), Neoglycoprotein, Asialoglycoprotein receptor imaging, Liver function, Liver diseases. |
|---|
| English |
|---|
| Title | Phase II Clinical Study on 99mTc-GSA, a New Agent for Functional Imaging of the Liver |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Kanji TORIZUKA*, San Kil Ha-KAWA**, Masatoshi KUDO***, Shinichi KITAGAWA****, Yoshitsugu KUBOTA****, Yoshimasa TANAKA**, Megumu HINO*****, Katsuji IKEKUBO***** |
|---|
| Authors(kana) | |
|---|
| Organization | *Fukui Medical School, **Department of Radiology, Kansai Medical University, ***Division of Gastroenterology, Department of Medicine, Kobe City General Hospital, ****Third Department of Internal Medicine, Kansai Medical University, ****Department of Nuclear Medicine, Kobe City General Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 29 |
|---|
| Number | 1 |
|---|
| Page | 85-95 |
|---|
| Year/Month | 1992/1 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]Phase II study of 99mTc-DTPA-galactosyl human serum albumin (99mTc-GSA), a new radiopharmaceutical which binds to the asialoglycoprotein receptors on the hepatocytes, was performed in 81 patients with liver diseases to validate its safety and possibility for the evaluation of hepatic function. None of adverse reactions, abnormal clinical laboratory findings and anti-99mTc-GSA antibody production due to 99mTc-GSA was recognized. Immediately after the injection of 99mTc-GSA, the dynamic data and serial hepatic images were obtained for 60 min. The indices for blood clearance and liver accumulation were calculated based on the counts in the regions of interest on the hearts and livers. In 54 patients with chronic hepatic disorders such as liver cirrhosis, the blood clearance and liver accumulation of 99mTc-GSA were retarded according to the progress of the hepatic disorders. The findings of 99mTc-GSA scintigraphy also reflected the hepatic functions of the patients with large hepatic tumors, obstructive jaundice and acute hepatitis. These results suggest that 99mTc-GSA has the clinical potentials to evaluate the liver functions in the patients with hepatic disorders. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Technetium-99m-DTPA-galactosyl human serum albumin (99mTc-GSA), Neoglycoprotein, Asialoglycoprotein receptor imaging, Liver function, Liver diseases. |
|---|